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Summary
Background Malawi, which has about 80 000 deaths from AIDS every year, made free antiretroviral therapy available 
to more than 80 000 patients between 2004 and 2006. We aimed to investigate mortality in a population before and 
after the introduction of free antiretroviral therapy, and therefore to assess the eﬀ ects of such programmes on survival 
at the population level.
Methods We used a demographic surveillance system to measure mortality in a population of 32 000 in northern 
Malawi, from August, 2002, when free antiretroviral therapy was not available in the study district, until 
February, 2006, 8 months after a clinic opened. Causes of death were established through verbal autopsies 
(retrospective interviews). Patients who registered for antiretroviral therapy at the clinic were identiﬁ ed and linked 
to the population under surveillance. Trends in mortality were analysed by age, sex, cause of death, and zone of 
residence.
Findings Before antiretroviral therapy became available in June, 2005, mortality in adults (aged 15–59 years) was 
9·8 deaths for 1000 person-years of observation (95% CI 8·9–10·9). The probability of dying between the ages of 15 
and 60 years was 43% (39–49) for men and 43% (38–47) for women; 229 of 352 deaths (65·1%) were attributed to 
AIDS. 8 months after the clinic that provided antiretroviral therapy opened, 107 adults from the study population had 
accessed treatment, out of an estimated 334 in need of treatment. Overall mortality in adults had decreased by 10% 
from 10·2 to 8·7 deaths for 1000 person-years of observation (adjusted rate ratio 0·90, 95% CI 0·70–1·14). Mortality 
was reduced by 35% (adjusted rate ratio 0·65, 0·46–0·92) in adults near the main road, where mortality before 
antiretroviral therapy was highest (from 13·2 to 8·5 deaths per 1000 person-years of observation before and after 
antiretroviral therapy). Mortality in adults aged 60 years or older did not change.
Interpretation Our ﬁ ndings of a reduction in mortality in adults aged between 15 and 59 years, with no change in 
those older than 60 years, suggests that deaths from AIDS were averted by the rapid scale-up of free antiretroviral 
therapy in rural Malawi, which led to a decline in adult mortality that was detectable at the population level.
Funding Wellcome Trust and British Leprosy Relief Association.
Introduction
The combination of high rates of HIV infection and the 
substantial decrease in life expectancy for people with 
untreated HIV/AIDS has changed mortality rates at the 
population level in many African countries.1 However, 
although this can be demonstrated in models, empirical 
evidence for this eﬀ ect on populations has been limited 
to a few community-based demographic surveillance 
studies2,3 since most African countries do not record 
vital registration data.4 Studies of changes in mortality 
rates associated with HIV/AIDS need information about 
the HIV status of individuals or about the causes of 
death, which can be ascertained by so-called verbal 
autopsies (retrospective interviews) or, more indirectly, 
by assessment of age-speciﬁ c and sex-speciﬁ c mor-
tality.5–7
Antiretroviral therapy greatly improves survival in HIV 
patients.8,9 Cohort studies have shown sustained 
reductions in mortality rates in treated patients, in both 
developing and developed countries.8,9 The scale-up of 
programmes for antiretroviral therapy is proceeding fast, 
to the extent that the survival beneﬁ ts might now be 
detectable at the population level.
In Malawi, adult HIV prevalence has stabilised at 
about 14% since the late 1990s.10 Antiretroviral therapy 
was ﬁ rst available in the central and southern regions, 
from three sites (two free and one with subsidised costs) 
that treated only 1500 people by 2002.11 With support 
from the Global Fund for AIDS, Tuberculosis and 
Malaria, a national programme providing free access to 
antiretroviral therapy began in Malawi in 2004, and by 
the end of December, 2006, 81 821 patients had registered 
for this treatment.12–14
As part of the Karonga Prevention Study in northern 
Malawi,15–19 we investigated the eﬀ ect of the introduction 
of antiretroviral therapy on HIV-related mortality within 
a population under a demographic surveillance system 
based on continuous registration.
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Methods
In 2002, we set up a demographic surveillance system 
based on continuous registration in a population of 32 000 
in Karonga district. The methods have been described in 
detail elsewhere.20 An initial house-to-house census 
recorded personal identiﬁ ers and socio demographic data 
for all individuals, and economic data and physical 
locations for all households. Continuous demo graphic 
surveillance was launched successively in 
230 geo graphically deﬁ ned clusters, each with 
15–60 households, immediately after completion of the 
census in the respective cluster. Within each cluster, one 
village informant was trained to record and report births, 
deaths, and migrations. Births and deaths were followed 
up every month by investigators, and migrations were 
checked every year. A new census of the total population, 
which was initiated 2 years after the start to assess the 
accuracy and completeness of continuous registration, 
showed that the routine system had registered 516 (99%) 
of 521 deaths, 1540 (97%) of 1588 births, and 12 115 (92%) 
of 13 168 migrations.20
The national programme of free (at the point of delivery) 
antiretroviral therapy started in June, 2004. At that time, 
the nearest clinic was located about 200 km from the study 
area. The ﬁ rst clinic that provided antiretroviral therapy in 
Karonga district opened in June, 2005, in Karonga town, 
which is 80 km from the study area. According to national 
guidelines, patients who had HIV/AIDS in WHO clinical 
stage 3 or 4 or in stage 2 with a CD4 cell count of less than 
250 cells per mm³ were started on a standard antiretroviral 
therapy regimen (of stavudine, lamivudine, and nevirapine) 
at the Karonga clinic.
Malawi’s north–south highway bisects the study area, 
and is the only tarmac road with public transport that 
links the study area to the town of Karonga. A short 
tarmac slip-road inside the study area leads to a small 
port and truck stop on the lake. Houses are typically 
scattered, in the north of Malawi, without obvious village 
boundaries, but the study area included a zone of higher 
density settlement, with local bars and trading centres 
located along the highway and by the truck stop at the 
lake. Previous ﬁ eldwork had shown that the population 
in this zone was more economically active and mobile 
than the rest of the population, and that HIV prevalence 
was much higher than in the more remote areas. A 
higher density zone around the tarmac roads was deﬁ ned 
to stratify the population geographically. We used 
ArcView 3.1 for spatial analysis to determine the distance 
from the midpoints of clusters to the nearest road. 
Figure 1 shows a map of the relative household density in 
the study area and the delineation of the 1 km zone 
around the tarmac roads. Clusters with midpoints within 
1 km of the roads covered 21% of the study area, and 
41 139 person-years (51% of the entire study population) 
were observed within this zone.
Each death was assigned to a cluster on the basis of the 
household membership of the deceased at the time of 
death. This deﬁ nition excluded short-term moves (eg, for 
nursing care) that might have occurred before the death. 
Health assistants with additional training did verbal 
autopsies for all deaths within the continuous registration 
area. They used a semistructured questionnaire that was 
based on the INDEPTH standardised verbal autopsies 
questionnaire,21 an adaptation of the standard WHO 
Household density
Karonga 80 km
Zone of clusters with midpoints
within 1 km of tarmac road 
0 km 5 km 10 km
Lake Malawi
Jetty slip road
North–south highway
–0·5 to 0·0 standard deviations
0·0 to 0·5 standard deviations
0·5 to 1·0 standard deviations
1·0 to 1·5 standard deviations
1·5 to 2·0 standard deviations
2·0 to 2·5 standard deviations
2·5 to 3·0 standard deviations
>3 standard deviations
N
Figure 1: Map of the study area showing the distribution of households
Grid of 250 m × 250 m relative to the mean household density in the whole study area (45 households per km2). The zone of clusters with midpoints within 1 km of 
the nearest road is marked.
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questionnaire. Questionnaire data for each person were 
supplemented by a review of patient-held health records, 
hospital case notes, and any previous HIV test results 
recorded by other related studies in the area. Since 2005, 
interviewers asked speciﬁ cally whether the deceased had 
been on antiretroviral therapy. Three medically or 
paramedically qualiﬁ ed individuals (medical doctors or 
clinical oﬃ  cers) independently reviewed each 
questionnaire to assign the most likely underlying cause 
of death. Direct causes of death (eg, cryptococcal 
meningitis in AIDS cases) were not coded. For deaths 
attributable to tuberculosis, HIV/AIDS was deﬁ ned as 
the underlying cause if symptoms of immunosuppression 
preceded the onset of cough or other symptoms of 
tuberculosis, or if the individual was known to be HIV 
positive. If the temporal sequence between signs of 
immunosuppression and tuberculosis was not clear, the 
cause of death was classiﬁ ed as “ tuberculosis or AIDS”. 
Discrepantly coded cases were discussed and resolved if 
possible, or coded as “non-speciﬁ able” if consensus could 
not be reached.
All patients who attended the Karonga clinic for 
antiretroviral therapy were also invited to participate in a 
separate operational study that consisted of active home 
follow-ups of non-attenders. More than 95% of patients 
consented to participate in that study, and their identity 
details were stored in a secured area of the central project 
database. Ethical approval for these studies was obtained 
from the National Health Sciences Research Committee 
of Malawi and the ethics committee of the London School 
of Hygiene and Tropical Medicine.
Statistical analysis
We assessed overall and cause-speciﬁ c mortality rates. To 
deﬁ ne the person-time denominator in the population, 
we observed every individual from the time they were 
ﬁ rst seen in the baseline census, from birth, or from the 
date of migration into the area after the baseline census, 
until the day of their death (if they were still a member of 
a household in the area at the time of death) or until 
migration out of the area. Multiple episodes of observation 
(and gaps) were allowed if individuals moved out of the 
surveillance area and later returned.
To allow comparison with other studies, crude and 
age-standardised death rates (for the whole population) 
and the age-standardised death rate for adults of 15 years 
and older are also presented, with direct standardisation 
to the INDEPTH standard population for sub-Saharan 
Africa.22 For the analysis of all-cause mortality, the failure 
event was death. To estimate AIDS-speciﬁ c mortality, the 
Men Women
15–44 years 45–59 years ≥60 years Total 15–44 years 45–59 years ≥60 years Total
Communicable diseases 83 (68·6%) 30 (56·6%) 22 (26·2%) 135 (52·3%) 115 (78·8%) 37 (69·8%) 29 (24·8%) 181 (57·3%)
HIV/AIDS 61 (50·4%) 22 (41·5%) 8 (9·5%) 91 (35·3%) 99 (67·8%) 32 (60·4%) 5 (4·3%) 136 (43·0%)
Tuberculosis or HIV/AIDS 6 (5·0%) 1 (1·9%) 0 7 (2·7%) 7 (4·8%) 1 (1·9%) 1 (0·9%) 9 (2·8%)
Tuberculosis 5 (4·1%) 0 1 (1·2%) 6 (2·3%) 0 2 (3·8%) 4 (3·4%) 6 (1·9%)
Pneumonia 2 (1·7%) 3 (5·7%) 6 (7·1%) 11 (4·3%) 2 (1·4%) 1 (1·9%) 8 (6·8%) 11 (3·5%)
Malaria 0 0 1 (1·2%) 1 (0·4%) 0 0 0 0
Acute febrile disease, 
non-speciﬁ able
3 (2·5%) 1 (1·9%) 0 4 (1·6%) 1 (0·7%) 0 7 (6·0%) 8 (2·5%)
Other communicable 
disease
6 (5·0%) 3 (5·7%) 6 (7·1%) 15 (5·8%) 6 (4·1%) 1 (1·9%) 4 (3·4%) 11 (3·5%)
Non-communicable 
diseases
15 (12·4%) 16 (30·2%) 44 (52·4%) 75 (29·1%) 23 (15·8%) 14 (26·4%) 58 (49·6%) 95 (30·1%)
Cardiovascular 0 6 (11·3%) 22 (26·2%) 28 (10·9%) 2 (1·4%) 8 (15·1%) 33 (28·2%) 43 (13·6%)
Gastrointestinal 7 (5·8%) 2 (3·8%) 6 (7·1%) 15 (5·8%) 5 (3·4%) 3 (5·7%) 7 (6·0%) 15 (4·7%)
Direct obstetric 0 0 0 0 11 (7·5%) 0 0 11 (3·5%)
Cancer 2 (1·7%) 2 (3·8%) 3 (3·6%) 7 (2·7%) 3 (2·1%) 2 (3·8%) 8 (6·8%) 13 (4·1%)
Endocrine 2 (1·7%) 1 (1·9%) 3 (3·6%) 6 (2·3%) 0 0 3 (2·6%) 3 (0·9%)
Respiratory 0 1 (1·9%) 0 1 (0·4%) 0 0 1 (0·9%) 1 (0·3%)
Other non-communicable 
disease
4 (3·3%) 4 (7·5%) 10 (11·9%) 18 (7·0%) 2 (1·4%) 1 (1·9%) 6 (5·1%) 9 (2·8%)
External causes 11 (9·1%) 4 (7·5%) 2 (2·4%) 17 (6·6%) 2 (1·4%) 1 (1·9%) 3 (2·6%) 6 (1·9%)
Accidental 8 (6·6%) 4 (7·5%) 1 (1·2%) 13 (5·0%) 2 (1·4%) 0 2 (1·7%) 4 (1·3%)
Suicide 1 (0·8%) 0 1 (1·2%) 2 (0·8%) 0 0 1 (0·9%) 1 (0·3%)
Homicide 0 0 0 0 0 1 (1·9%) 0 1 (0·3%)
Unknown intent 2 (1·7%) 0 0 2 (0·8%) 0 0 0 0
Cause of death unknown 12 (9·9%) 3 (5·7%) 16 (19·0%) 31 (12·0%) 6 (4·1%) 1 (1·9%) 27 (23·1%) 34 (10·8%)
Total 121 (100·0%) 53 (100·0%) 84 (100·0%) 258 (100·0%) 146 (100·0%) 53 (100·0%) 117 (100·0%) 316 (100·0%)
Table 1: Probable causes of death in 574 adults aged older than 14 years
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failure event was death from AIDS or “tuberculosis or 
AIDS”; deaths from all other known and unknown causes 
were censored. To estimate mortality from all other 
causes except AIDS, we censored deaths from AIDS and 
deaths from tuberculosis or AIDS.
Because of the staggered start of the baseline census for 
continuous registration, geographical areas con tributed 
diﬀ erent amounts of observation time in diﬀ erent 
calendar periods. We therefore calculated the probability 
of dying between certain ages before antiretroviral therapy 
was available with a Poisson regression model, weighted 
by the relative population size in the diﬀ erent enumeration 
areas. The lifetime risk of dying of HIV/AIDS23 was 
calculated from the Kaplan-Meier failure function as the 
cumulative probability of dying from AIDS when the 
curve reached its plateau (at 70 years of age).
To assess the eﬀ ect of antiretroviral therapy, mortality 
rates were initially compared between three periods: 
before the start of the national roll-out, when antiretroviral 
therapy became available in the northern region, and 
when antiretroviral therapy became available in Karonga 
Town. Since mortality rates had not changed before the 
opening of the Karonga clinic (data not shown), we 
compared mortality rates in the ﬁ rst two periods combined, 
with those from the last period. To allow for the staggered 
start of the baseline census, we adjusted mortality rate 
ratios for enumeration area. We also adjusted them for 
age and sex to account for potential changes in age 
distribution and sex ratio over time. The Poisson 
regression model was stratiﬁ ed according to age (15–29, 
30–44, 45–59, and 60 years and older) and according to the 
distance of each area of residence to the nearest tarmac 
road (whether 1 km or less, or more than 1 km).
Role of the funding source
The sponsors of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had ﬁ nal 
responsibility for the decision to submit for publication.
Results
Between August, 2002, and the end of February, 2006, we 
recorded 916 deaths in 39 321 individuals during 
81 278 person-years of observation, which equates to a 
crude death rate of 11 per 1000 per year (95% CI 
10·6–12·0) and an age-standardised death rate of 12 per 
1000 person-years of observation. Of these deaths, 
574 were in adults older than 14 years (for whom we 
recorded 42 657 person-years of observation), and 
373 deaths were in 18 927 adults aged 15–59 years (with 
38 015 person-years of observation). Therefore, the adult 
mortality rate was 9·8 per 1000 person-years of 
observation (95% CI 8·9–10·9), with 9·6 (8·3–11·1) in 
men and 10·0 (8·6–11·5) in women.
269 (46·9%) of the 574 deaths in adults older than 
14 years occurred at health facilities, 262 (45·6%) at 
home, 30 (5·2%) outdoors, and 13 (2·3%) at traditional 
healer camps. Table 1 shows the probable causes for these 
574 deaths. Verbal autopsies were available for 
570 (99·3%), and a probable cause was established for 
509 deaths (227 [88%] of men and 282 [89%] of women). 
More female than male deaths were attributed to AIDS: 
145 (51%) of 282 women died of AIDS, compared with 98 
(43%) of 227 men (p=0·065).
Of the 373 deaths in adults aged 15–59 years, verbal 
autopsies were available for 372 (99·4%). In this 
age-group, probable causes were established for 
352 deaths (159 [91·4%] of deaths in men and 192 [96·5%] 
in women). 229 (65·1%) of these 352 deaths were 
attributed to AIDS. 139 (72·0%) women and 90 (56·6%) 
men died of AIDS—ie, 60·7% of all AIDS deaths were in 
women.
Mortality rates from all causes by sex and age in the 
period before antiretroviral therapy was introduced in 
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Figure 2: Mortality rates by sex and age-group before availability of antiretroviral therapy
Data are from August, 2002 to June, 2005, with 438 deaths in 31 665 person-years of observation.
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June 2005 are shown in Figure 2. Death rates initially 
peaked between the ages of 40 and 44 years for both men 
and women, and then rose again at later ages. Death 
rates increased at an earlier age in women than in men; 
and were 3·4 times higher (95% CI 1·3–8·9) at age 
20–24 years (adjusted for area). This diﬀ erential was lost 
by the ages of 30–34 years, and at older ages rates of death 
in women were slightly lower than in men. Figure 2 also 
shows age-speciﬁ c and sex-speciﬁ c mortality from AIDS 
and from all other causes combined for the same period; 
the high mortality in young women and the peak between 
the ages of 40 and 44 years is clearly attributable to AIDS. 
Overall adult mortality from all causes was almost 
identical in women and men (rate ratio [RR] adjusted for 
age and area 0·97, 95% CI 0·81–1·17), but AIDS-speciﬁ c 
mortality was higher in women (RR adjusted for age and 
area 1·36, 1·01–1·82). The overall age-standardised AIDS 
mortality rate in adults older than 14 years was 6·3 deaths 
per 1000 person-years of observation, with 4·9 in men 
and 6·5 in women.
Figure 3 and table 2 show survival probability by age 
and adult mortality risks in the period before 
antiretroviral therapy. Before the opening of the 
Karonga clinic, the probability of dying from any cause 
between the exact ages of 15 and 60 years (45q15, 
adjusted for area) was 43% (95% CI 39–49) for men and 
43% (38–47) for women. Of the 289 deaths in adults 
aged 15–59 years in this period, 181 (63%) were 
attributed to AIDS. The probability of dying of any 
cause other than AIDS between ages 15 and 60 years 
(45q15, adjusted for area) was 19% (95% CI 15–25) for 
men and 15% (12–20) for women. Two other measures 
for the probability of dying are shown in table 2 to allow 
comparison with other studies. Assuming unchanged 
HIV-incidence and mortality, a child born into the 
surveillance population before the introduction of 
antiretroviral therapy would have had a 37% lifetime 
risk of dying from AIDS (35% for boys and 38% for 
girls).
Overall mortality rates before and after opening of the 
antiretroviral therapy clinic in Karonga district are shown 
in table 3. After the opening of the clinic, all-cause 
mortality in adults aged 15–59 years decreased by 10% 
(the rate ratio [RR] adjusted for age, sex, and area 
was 0·90, 95% CI 0·70–1·15), which is equivalent to nine 
deaths averted in the 8-month observation period after 
introduction of antiretroviral therapy. All-cause mortality 
in individuals aged 60 years and older did not change. 
AIDS mortality decreased by 19% in the 15–59-year 
age-group (adjusted RR 0·81, 0·58–1·12), with no change 
in mortality from causes other than AIDS.
Trends in adult mortality diﬀ ered in the two zones 
that were deﬁ ned according to distance from the tarmac 
road (p=0·003, test for interaction in adults aged 
15–59 years). Mortality in adults aged 15–59 years before 
the introduction of antiretroviral therapy was much 
higher in the 1 km zone close to the tarmac roads than 
in the rest of the study area (rate ratio [RR] 1·91, 95% CI 
1·49–2·48). Table 3 shows that the mortality rate was 
reduced by 35% in adults aged 15–59 years who lived 
within 1 km of the tarmac roads (RR adjusted for age 
and area 0·65, 0·46–0·92) after the opening of the 
antiretroviral therapy clinic. Reductions were seen in 
each of the age-groups, 15–29, 30–44, and 45–59 years. 
In the zone further away from the road, mortality 
increased slightly in those aged 15–59 years. Mortality 
rates in adults aged 60 years or older did not change in 
either zone (area-adjusted RR: 1 km-zone 0·99, remote 
zone 1·03).
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Figure 3: Kaplan–Meier survival function for the entire study population before introduction of 
antiretroviral therapy
Data are from August, 2002, to June, 2005, with 438 deaths in 31 665 person-years of observation.
All-cause mortality Mortality from all causes except AIDS
Deaths Person-years of observation Probability Deaths Person-years of observation Probability
All Men Women All Men Women All Men Women All Men Women All Men Women All Men Women
Ages 15–60 years 289 131 158 28 244 13 459 14 786 43% 43% 43% 89 51 38 28 244 13 459 14 786 17% 19% 15%
Ages 20–50 years 229 103 126 19 696 9372 10 323 30% 31% 30% 57 33 24 19 696 9 372 10 323 10% 12% 9%
Ages 30–65 years 244 124 120 12 685 5772 6913 45% 45% 44% 76 46 30 12 685 5 772 6913 20% 22% 18%
Table 2: Probability of dying between the ages of 15 and 60, 20 and 50, and 30 and 65 years in the surveillance population before opening of the antiretroviral therapy clinic in 
June, 2005, adjusted for area
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In the zone within 1 km of the tarmac roads, AIDS 
mortality in adults aged 15–59 years was reduced by 33% 
after the opening of the Karonga antiretroviral therapy 
clinic (rate ratio [RR], adjusted for age, sex, and area 0·67, 
95% CI 0·44–1·03) and little change was seen in the 
more remote zone (RR, adjusted for age, sex, and 
area 1·07, 0·64–1·79). Deaths that were classiﬁ ed as not 
related to AIDS also decreased close to the road (RR 
adjusted for age, sex, and area 0·57, 0·30–1·10), but 
increased further from the road (RR adjusted for age, 
sex, and area 2·36, 1·32–4·20). 11 men and 12 women 
died of causes other than AIDS in the remote zone after 
the introduction of antiretroviral therapy (ﬁ ve from 
gastrointestinal causes, four cardiovascular, four cancer, 
three meningitis, three accidents, two from tuberculosis, 
and one maternal death). Of adults aged 15–59 years who 
died, three had moved from the near zone to the more 
remote zone and two in the other direction before the 
introduction of antiretroviral therapy. After the clinic 
opened, three moved from the near to the more remote 
zone.
By the end of the observation period, in February, 2006, 
99 adults from the study population had accessed 
antiretroviral therapy at the Karonga clinic and 12 of 
these (seven women and ﬁ ve men) died during the 
observation period. The verbal autopsies revealed that 
an additional eight adults (ﬁ ve women and three men) 
had received antiretroviral therapy before their death, 
but had not been identiﬁ ed at the Karonga clinic and 
therefore apparently received treatment from another 
source, some probably before the opening of the 
Karonga clinic in June, 2005. Overall 12 women and 
All causes Adults 15–59 years
15–29 years 30–44 years 45–59 years ≥ 60 years 15–59 years All ≥15 years AIDS death Non-AIDS 
death
Unknown cause 
of death
Entire study population
Before antiretroviral therapy
Deaths 59 148 82 149 289 438 181 89 19
Person-years of observation 16 347 7866 4031 3421 28 244 31 665 28 244 28 244 28 244
Deaths per 1000 person-years of observation 3·6 18·8 20·3 43·6 10·2 13·8 6·4 3·2 0·7
After antiretroviral therapy
Deaths 16 44 25 51 85 136 48 34 3
Person-years of observation 5587 2840 1344 1220 9771 10 991 9771 9771 9771
Deaths per 1000 person-years of observation 2·9 15·5 18·6 41·8 8·7 12·4 4·9 3·5 0·3
Adjusted rate ratio 0·83* 
(0·47–1·47)
0·86* 
(0·61–1·21)
0·98* 
(0·62–1·56)
1·00* 
(0·73–1·38)
0·90† 
(0·70–1·15)
0·94† 
(0·77–1·14)
0·81† 
(0·58–1·12)
1·16† 
(0·77–1·75)
0·52† 
(0·16–1·70)
Area closer than 1 km to the road
Before antiretroviral therapy
Deaths 35 105 56 85 196 281 124 61 11
Person-years of observation 8695 4119 1985 1814 14 799 16 613 14 799 14 799 14 799
Deaths per 1000 person-years of observation 4·0 25·5 28·2 46·9 13·2 16·9 8·4 4·1 0·7
After antiretroviral therapy
Deaths 9 20 11 27 40 67 26 11 3
Person-years of observation 2 713 1368 638 582 4720 5302 4720 4720 4720
Deaths per 1000 person-years of observation 3·3 14·6 17·2 46·4 8·5 12·6 5·5 2·3 0·6
Adjusted rate ratio 0·84* 
(0·40–1·80)
0·58* 
(0·36–0·94)
0·64* 
(0·33–1·24)
0·99* 
(0·64–1·52)
0·65† 
(0·46–0·92)
0·76† 
(0·57–0·99)
0·67† 
(0·44–1·03)
0·57† 
(0·30–1·10)
0·88† 
(0·25–3·04)
Area further than 1 km from the road
Before antiretroviral therapy
Deaths 24 43 26 64 93 157 57 28 8
Person-years of observation 7651 3747 2047 1607 13 445 15 052 13 445 13 445 13 445
Deaths per 1000 person-years of observation 3·1 11·5 12·7 39·8 6·9 10·4 4·2 2·1 0·6
After antiretroviral therapy
Deaths 7 24 14 24 45 69 22 23 0
Person-years of observation 2873 1472 706 638 5052 5689 5052 5052 5052
Deaths per 1000 person-years of observation 2·4 16·3 19·8 37·6 8·9 12·1 4·4 4·6 0
Adjusted rate ratio 0·82* 
(0·35–1·94)
1·48* 
(0·88–2·49)
1·72* 
(0·87–3·31)
1·03* 
(0·64–1·66)
1·37† 
(0·94–1·98)
1·24† 
(0·92–1·65)
1·07† 
(0·64–1·79)
2·36† 
(1·32–4·20)
..
*Rate ratio, adjusted for area and sex, with 95% CI. †Rate ratio, adjusted for area, sex, and age, with 95% CI.
Table 3: Trends in adult mortality before and after opening of the antiretroviral clinic in Karonga district
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eight men who had antiretroviral therapy died during 
the observation period (accounting for 8% of AIDS 
deaths).
Of all 107 adults (74 women and 33 men) known to have 
accessed antiretroviral therapy, 78 (73%) lived within 
1 km of the tarmac roads. The rate of access per 
person-years of observation in people near the road was 
2·6 times that in the more distant zone (p<0·0001).
Discussion
Malawi’s population of 12·5 million has been severely 
aﬀ ected by a generalised HIV epidemic since the 
early 1990s. In the absence of a vital registration system 
or reliable mortality statistics from the health services, 
AIDS mortality has been estimated with mathematical 
models (EPP and Spectrum)24 based on HIV-prevalence 
data from antenatal sentinel surveillance. More than half 
of all adults who died in the study population did so 
outside of health facilities, which is typical of other rural 
African settings,25,26 and explains why facility-based 
analyses of mortality would not be representative in these 
settings. 
Analysis of age-speciﬁ c mortality and survival in the 
population showed that premature deaths of adults aged 
15–59 years were associated with the eﬀ ect of the HIV 
epidemic. Before the antiretroviral therapy clinic opened, 
the probablility of dying between the ages of 15 and 
60 years for men was 43%, and 63% of deaths in this 
age-group were attributed to AIDS. This is in line with 
other studies when the prevalence of HIV is taken into 
account. Adult HIV-prevalence in the study population 
in 2005 was about 11·4%,27 which was lower than national 
estimates of 14·4% in 2003 from antenatal surveillance24 
and 12% in 2004 from a general population sample.28 
Based on the assumed national prevalence of 14·4%, 
WHO models predict a mortality risk in men aged 
between 15 and 60 years of 66% for Malawi. In the era 
before the HIV epidemic, male adult mortality in 
sub-Saharan Africa was assumed to range between 20% 
and 50%, and values below 40% have been projected for 
countries with low HIV prevalence in West and Central 
Africa.29 A review of WHO and UNAIDS projections 
showed estimates of greater than 60% for adult mortality 
in nine of 12 countries in sub-Saharan Africa that had 
HIV prevalences of more than 10%.29 Our result for the 
mortality rate from AIDS in adults, standardised for age 
(6·3 deaths per 1000 person-years of observation), was 
much higher than empirical estimates, based on verbal 
autopsies from three other demographic surveillance 
sites. In Tanzania, which had a lower prevalence of HIV, 
the rates were 1·3 deaths per 1000 person-years of 
observation in Ruﬁ ji and 1·8 in Ifakara.30 In Manhiça, 
Mozambique, the rate was 2·4 deaths per 1000 person-
years of observation.30 In KwaZulu Natal, South Africa, 
where the HIV prevalence was estimated at 21·5% in 
2003–04,31 the rate was 11·4 per 1000 person-years of 
observation.30
Our results show not only the eﬀ ect of HIV on mortality 
at the population level, but also the beginning of a 
reversal of this eﬀ ect by antiretroviral therapy. After the 
opening of the ﬁ rst clinic in the district, mortality rates 
fell by 10% in 15–59-year-olds. In the area close to the 
roads, where baseline mortality rates were much higher, 
associated with higher HIV prevalences,32 all-cause 
mortality fell by 35% (rate ratio 0·65, 0·46–0·92).
Detection of eﬀ ects at the population level such a 
short time after the introduction of antiretroviral 
therapy in the district might seem surprising, but could 
be expected from the high proportion of deaths 
attributable to HIV before the clinic opened (65%), the 
high HIV prevalence (11% overall and higher near the 
road), good uptake of antiretroviral therapy, and the 
ability of such treatment to prevent deaths which would 
otherwise be imminent.
Using mathematical models ﬁ tted to repeated surveys 
of the seroprevalence of HIV, we have previously 
estimated that about 2% of adults in Karonga district 
needed antiretroviral therapy in 2005 (ie, would have 
died within 2 years).33 If we assume that the demographic 
surveillance area is typical of the district as a whole, 
334 of the 16 720 adults aged 15 years and older in the 
surveillance population needed treatment. By the end of 
February, 2006, 8 months after the opening of the 
Karonga clinic, 107 adults in the study population—
almost a third of those who were in need—had accessed 
antiretroviral therapy. 60·1% of all patients at the clinic 
were women. That a similar proportion (60∙7%) of AIDS 
deaths in our study population were in women suggests 
that access to treatment was balanced between the sexes. 
A community-based study from the era before anti-
retroviral therapy in Malawi reported high rates of 
mortality in HIV patients eligible for antiretroviral 
therapy (62 and 88 deaths per 100 person-years of 
observation for patients in clinical stages 3 and 4, 
respectively).34 Data from the programme in Malawi 
have shown that 81% of patients survived after 6 months 
of antiretroviral therapy, and 74% after 12 months.35 Data 
from the Ministry of Health’s routine monitoring of the 
Karonga clinic show that of 1091 patients who registered 
from June, 2005, to September, 2006, 452 (41·4%) were 
in clinical stage 3 and 615 (56·4%) were in stage 4. The 
mortality risk was 25·0% within the ﬁ rst 6 months after 
initiation of antiretroviral therapy and declined rapidly 
with time on antiretroviral therapy: only 41 (19·4%) of 
the 211 deaths occurred after the third month 
(Prof AD Harries, personal communication). Of the 
99 patients of the Karonga clinic who were in the study 
population, 66 (66·7%) had initiated antiretroviral 
therapy before December, 2005—ie, more than 3 months 
before the end of the observation period. With respect to 
the substantial eﬀ ect that antiretroviral therapy has on 
survival and the large number of adults in the 
surveillance population who had accessed antiretroviral 
therapy, our ﬁ ndings about reductions in mortality in 
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the study population can plausibly be attributed to 
antiretroviral therapy.
This high uptake of antiretroviral therapy in the study 
area is encouraging, especially since, although treatment 
was free, visits to the clinic cost about US$3 by public 
transport, whereas the average monthly household 
income in this population was US$23 in 2004.36
Our ﬁ nding that deaths not related to AIDS decreased 
in the zone near the main roads but not in the more 
remote zone might be attributable to some 
misclassiﬁ cation in causes of death. Some of the 23 deaths 
attributed to other causes (eg, the three deaths from 
meningitis and two from tuberculosis) could in fact have 
been due to HIV. Previous studies have shown that 
analyses of verbal autopsies alone, without knowledge of 
HIV status, can underestimate deaths caused by AIDS.37 
Therefore, assessments of mortality due to AIDS by use 
of verbal autopsies alone might not be valid.38 Systematic 
assessments of the ascertainment of AIDS deaths by 
verbal autopsies have shown that their sensitivity ranges 
from 76%39 to 92%,40 and that they have a speciﬁ city 
of 66% compared with diagnoses based on HIV 
serostatus.39 HIV status was only known for a few of 
those who died. The proportion of individuals with 
known HIV status rose later in the study. 19% of those 
who died in the near zone before treatment was available 
were known to be HIV positive, compared with 30% of 
those who died after the clinic was set up; further from 
the road the proportions were 13% and 16%, respectively. 
The increase in the availability of positive results after the 
clinic opened could have increased the proportion of 
deaths attributed to AIDS in the zone close to the road, 
and contributes to the apparent decline in other deaths in 
this area.
Since few people moved between the two zones, the 
observed changes in mortality cannot be explained by 
migration. The rate of deaths from causes other than 
AIDS was relatively low in the more remote zone before 
the clinic opened, which could have contributed to the 
apparent rise in such deaths in this area. 
The fact that mortality fell in the age-group known to 
be aﬀ ected most by AIDS mortality (15–59 years), but 
remained unchanged in older adults, adds credence to 
the interpretation that the observed trend was due to a 
reduction in AIDS deaths. Other external changes (eg, in 
the food supply) would be expected to increase mortality 
more in older than in younger adults.
The surveillance area contained about 12% of the adult 
population of the district but 16% of those who attended 
the Karonga clinic. This suggests that access to 
antiretroviral treatment in the study area was slightly 
higher than average in the population. Implementation 
of antiretroviral therapy across Malawi continues to 
accelerate, including a new public clinic in the surveillance 
area since September, 2006. With continuing decentral-
isation and increased access, population mor tality rates 
should continue to fall.
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